Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. [electronic resource]
Producer: 20050418Description: 2121-43 p. digitalISSN:- 0950-9232
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD -- drug effects
- Antigens, CD20 -- drug effects
- Antineoplastic Agents -- therapeutic use
- Cell Survival -- drug effects
- Cloning, Molecular
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Mice
- Recombinant Fusion Proteins -- therapeutic use
- Rituximab
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.